RE:RE:Regarding the transcript…lots of good & great stuff
I am kinda wondering how AN might fit into all of this as to whether they will just run a concurrent trial incorporating the results from Aware1 and Bracelet. It will be interesting to see how much empahsis will be put on the biomarkers as there was hardly any mention of it in the quarterly cc when talking about the trial design so am hoping that onc will provide more clarity once asco results are revealed.
I do like that the AN bridging trial basically confirmed what we know from the onc mbc trial so one would think or hope that these results would similarily translate across to the bracelet trial.
Will AN be a player in all of this will be most intersting as they do already have a partnership with onc and would they have the backing or clout for a possible bid for the company if a BO is being considered as I am thinking that any company interested in a possible BO would then know that they have inroads into the Asian market.
So much to ponder and hopefully a lot more clarity with ASCO